Trademark Overview
On Wednesday, June 3, 2026, a trademark application was filed for MAVFORO with the United States Patent and Trademark Office. The USPTO has given the MAVFORO trademark a serial number of 99862334. The federal status of this trademark filing is PUBLICATION/ISSUE REVIEW COMPLETE as of Thursday, June 18, 2026. This trademark is owned by Glaxo Group Limited. The MAVFORO trademark is filed in the Pharmaceutical Products category with the following description:
Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders; Pharmaceutical preparations for the prevention of infectious diseases; Vaccines; Anti-infectives